<DOC>
	<DOCNO>NCT00784914</DOCNO>
	<brief_summary>RATIONALE : Temsirolimus may stop growth tumor cell block enzymes need cell growth . Studying sample blood tumor tissue patient cancer laboratory may help doctor learn treatment use body . PURPOSE : The purpose study evaluate feasibility use microdialysis catheter see effect temsirolimus various biological substance associate brain tumor time .</brief_summary>
	<brief_title>A Feasibility , Dose-Escalation Study Using Intracerebral Microdialysis Assess Neuropharmacodynamics Temsirolimus Patients With Primary Metastatic Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility use microdialysis catheter high cut-off membrane perform neuropharmacodynamics ( nPD ) assessment target therapy mammalian target rapamycin ( mTOR ) inhibitor , nPD define change intracerebral level vascular endothelial growth factor ( VEGF ) , interleukin-1ß ( IL-1ß ) , cytokine . Secondary - Assess relationship temsirolimus dose change intracerebral level VEGF , IL-1ß , cytokine . - Compare change intracerebral cytokine level change systemic cytokine level . - Assess relationship degree microvascular proliferation tensin homologue delete chromosome 10 ( PTEN ) status tumor tissue . - Assess relationship change intracerebral cytokine level treatment temsirolimus . OUTLINE : Two cohort 6 patient enrol study . All patient undergo debulking craniotomy stereotactic biopsy placement intracerebral CMA 71 microdialysis ( ICMD ) catheter . Patients assign 1 2 treatment cohort . - Cohort 1 : Patients receive temsirolimus . Dialysate sample collect regular interval 96 hour follow placement catheter well serial blood sample measure level cytokine , chemokines growth factor occur neurosurgery . - Cohort 2 : Beginning 48 hour surgery , patient receive single 200 mg dose temsirolimus IV . Dialysate sample collect regular interval 96 hour follow placement catheter well serial blood sample measure level cytokine , chemokines growth factor occur neurosurgery . Plasma level temsirolimus sirolimus also measure serial blood sample . After completion study therapy removal ICMD catheter , patient follow 30 day .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria Patients must least 18 year age . Patients must either primary metastatic brain tumor ( ) . Patients must need surgical debulking stereotactic biopsy purpose diagnosis differentiate tumor progression treatmentinduced effect follow radiation therapy + chemotherapy . For patient cohort 2 , treatment temsirolimus must contraindicate . Patients cohort 2 must take hepatic enzymeinducing anticonvulsant ( phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) . Patients take strong CYP3A4 inducer inhibitor clarithromycin , itraconazole , ketoconazole , nefazodone , telithromycin , rifampin , rifabutin , rifampacin , St. John 's Wort must discontinue medication begin least one week prior surgery last duration study . The exception dexamethasone use postoperatively indicated . Patients must Karnofsky Performance Status &gt; = 60 % ECOG/Zubrod score &lt; = 2 . Patients must recover toxicity prior therapy . Patients must adequate bone marrow function ( define absolute neutrophil count &gt; = 1500 cells/mm3 platelet count ≥ 100,000 cells/mm3 ) , liver function total bilirubin &lt; = 2.0 mg/dl AST ( SGOT ) &lt; = 4 time institutional upper limit normal , serum creatinine &lt; =1.5 x institutional upper limit normal . Patients must able understand willing sign write informed consent document . The effect temsirolimus develop fetus unknown . Therefore , female patient childbearing potential sexuallyactive male patient must agree use effective method contraception participate study . Women childbearing potential must negative pregnancy test &lt; =2 week prior registration . Exclusion Criteria Patients must plan receive radiation , chemotherapy participate another clinical trial time surgery microdialysis catheter remove . Patients allergic temsirolimus , sirolimus ( rapamycin ) , Dextran . Patients coagulopathy , increased susceptibility infection bleed disorder . Patients anticoagulant drug therapy . Patients uncontrolled diabetes . Patients serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Female patient pregnant breastfeeding . HIVpositive patient receive antiretroviral therapy exclude study due possibility PK interaction temsirolimus ; however , patient routinely screen HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>meningeal melanocytoma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>adult pineocytoma</keyword>
</DOC>